ITGB2 and breast cancer: Taken together, our results and those of others [17] suggest that the microenvironments of different tumors, such as breast cancer, and TDLNs drive an upregulation of CD18 in neutrophils, which might be essential to neutrophil-mediated suppression of anti-cancer immune responses.